1,618 reports of this reaction
3.7% of all ORLISTAT reports
#8 most reported adverse reaction
FLATULENCE is the #8 most commonly reported adverse reaction for ORLISTAT, manufactured by Haleon US Holdings LLC. There are 1,618 FDA adverse event reports linking ORLISTAT to FLATULENCE. This represents approximately 3.7% of all 43,367 adverse event reports for this drug.
Patients taking ORLISTAT who experience flatulence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLATULENCE is moderately reported among ORLISTAT users, representing a notable but not dominant share of adverse events.
In addition to flatulence, the following adverse reactions have been reported for ORLISTAT:
The following drugs have also been linked to flatulence in FDA adverse event reports:
FLATULENCE has been reported as an adverse event in 1,618 FDA reports for ORLISTAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLATULENCE accounts for approximately 3.7% of all adverse event reports for ORLISTAT, making it a notable side effect.
If you experience flatulence while taking ORLISTAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.